Literature DB >> 17995974

Response to 'Communicating information about drug interactions'.

David J Back, Sara E Gibbons.   

Abstract

Mesh：

Substances：

Year:  2007        PMID： 17995974      PMCID： PMC2291362          DOI： 10.1111/j.1365-2125.2007.03043.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  4 in total

1.  Evaluation of HIV drug interaction web sites.

Authors:  Nancy L Sheehan; Deborah V Kelly; Alice L Tseng; Rolf P G van Heeswijk; Lizanne C Béïque; Christine A Hughes
Journal:  Ann Pharmacother       Date:  2003-11       Impact factor: 3.154

2.  Comparative assessment of four drug interaction compendia.

Authors:  Agnes I Vitry
Journal:  Br J Clin Pharmacol       Date:  2006-12-07       Impact factor: 4.335

3.  Reasons for stopping antiretrovirals used in an initial highly active antiretroviral regimen: increased incidence of stopping due to toxicity or patient/physician choice in patients with hepatitis C coinfection.

Authors:  A Mocroft; A N Phillips; V Soriano; J Rockstroh; A Blaxhult; C Katlama; A Boron-Kaczmarska; L Viksna; O Kirk; J D Lundgren
Journal:  AIDS Res Hum Retroviruses       Date:  2005-09       Impact factor: 2.205

4.  Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients.

Authors:  Munir Pirmohamed; Sally James; Shaun Meakin; Chris Green; Andrew K Scott; Thomas J Walley; Keith Farrar; B Kevin Park; Alasdair M Breckenridge
Journal:  BMJ       Date:  2004-07-03
  4 in total
  1 in total

1.  Minimising harm: human variation and adverse drug reactions (ADRs).

Authors:  J M Ritter
Journal:  Br J Clin Pharmacol       Date:  2008-04       Impact factor: 4.335
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.